You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available [see all tables in this series...]

Part (iii) Demographics of all men entering treatment

Country		Year	Mean age	% Age <25	% Age 35+
Bulgaria		2005	24.4	57.8	3.1
Czech Republic		2005	25.2	52.3	9.9
Denmark		2005	31.5	26.8	35.2
Germany		2005	29.2	38.4	25.4
Ireland		2005	28.3	40.3	15.5
Greece		2005	30.1	31.1	21.2
Spain	(1)	2004	31.9	22.1	38.0
France		2005	27.9	41.0	22.8
Italy	(2)	2005	32.0	23.4	35.7
Cyprus		2005	28.5	35.2	21.8
Latvia	(3)	2005	22.2	66.7	8.8
Lithuania		2005	30.3	30.4	23.9
Luxembourg		2005	31.3	24.0	34.0
Hungary		2005	26.0	49.0	15.0
Malta		2005	25.3	53.5	13.7
Netherlands		2005	33.1	23.1	40.6
Austria	(4)	2005	34.2	17.9	47.5
Poland	(1)	2004	27.0	53.0	18.1
Portugal	(3)	2005	32.0	20.0	36.8
Romania		2005	30.7	43.0	26.0
Slovenia	(1)	2004	27.5	36.0	14.0
Slovakia		2005	24.9	54.8	7.0
Finland		2005	28.0	41.0	20.0
Sweden		2005	32.0	25.3	39.5
United Kingdom	(5)	2005	30.5	27.6	28.7
Turkey		2005	30.3	29.0	30.0

Notes:

Data were not available for: Belgium, Estonia, Norway.

(1) Last data available refer to 2004.

(2) Until 2004, 'all clients' reported clients continuing in or entering treatment in reported year; 2005 data are conformant with the TDI protocol.

(3) Data by gender refer to first treatments.

(4) Data refer to clients in substitution treatment only; figures for opioids as main drug and injecting use are 100%.

(5) Data relate to the period from 1 April 2004 to 31 March 2005 for UK.

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

2006 Reitox national reports - Standard table 3 See [Table TDI-1 Part (0)] for details on sources.